HCRTR2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL441256	1.00	20/20
SCHEMBL439572	0.87	20/20
SCHEMBL439578	0.83	20/20
SCHEMBL441336	0.83	20/20
SCHEMBL439577	0.79	20/20
SCHEMBL439302	0.73	20/20
SCHEMBL439583	0.70	20/20
SCHEMBL441337	0.69	20/20
SCHEMBL439303	0.67	20/20
SCHEMBL440922	0.65	20/20
SCHEMBL439310	0.62	20/20
SCHEMBL441347	0.59	20/20
SCHEMBL441240	0.58	20/20
SCHEMBL204028	0.58	20/20
SCHEMBL80489	0.56	20/20
SCHEMBL312157	0.55	20/20
SCHEMBL311133	0.54	20/20
SCHEMBL312541	0.54	20/20
SCHEMBL270166	1.00	19/20
SCHEMBL269848	0.86	19/20

Clinical trials — most relevant to HCRTR2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease	PHASE4	NOT_YET_RECRUITING
Lemborexant Shift Work Treatment Study	PHASE4	COMPLETED
Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease	PHASE4	RECRUITING
Lemborexant for Insomnia in a Patient With Dementia: An N-of-1 Trial	PHASE4	RECRUITING
Lemborexant in Delayed Sleep Phase Syndrome	PHASE4	COMPLETED
The Role of Orexin in Human Panic Disorder	PHASE4	COMPLETED
Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep	PHASE3	COMPLETED
The Efficacy of Suvorexant in Treatment of Patients With Substance Use Disorder and Insomnia: A Pilot Open Trial	PHASE2/PHASE3	COMPLETED
A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy	PHASE3	COMPLETED
Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy.	PHASE3	COMPLETED
Safety and Efficacy Study of Ramelteon in Subjects With Chronic Insomnia	PHASE3	COMPLETED
DORA and LP in Alzheimer's Disease Biomarkers	PHASE2	RECRUITING
Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use	PHASE2	COMPLETED
Analyzing Female Trauma Exposed Responses to a Medication	PHASE2	COMPLETED
Daridorexant for Alzheimer Disease Prevention	PHASE2	RECRUITING
Effects of Eszopiclone and Lemborexant in People With OSA With a Low Arousal Threshold Who Have Difficulty Sleeping	PHASE2	NOT_YET_RECRUITING
Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA)	PHASE2	COMPLETED
Targeting Orexin to Treat Nicotine Dependence	PHASE1	UNKNOWN
Phase 1 TAK-925 Study in Healthy Adult and Elderly Volunteers and Participants With Narcolepsy	PHASE1	COMPLETED
Oral Dexmedetomidine in Pediatric MRI	PHASE1	NOT_YET_RECRUITING
Effect of Orexin System on Nicotine Addiction and Its Neural Mechanism	nan	NOT_YET_RECRUITING
Constitution of a Clinical, Neurophysiological and Biological Cohort for Chronic Sleep Disorders Responsible of Hypersomnolence	nan	RECRUITING
Genetic and Clinical Characterization of Type 1 and 2 Narcolepsy in Adult and Pediatric Black and North African Populations	nan	NOT_YET_RECRUITING
Auricular Vagus Stimulation in Obesity	nan	ACTIVE_NOT_RECRUITING
Difference of Plasma Orexin A Levels Between Elderly and Young Patients at Emergence	nan	UNKNOWN
Digital Addiction, Sleep Quality and Orexin-A Level	nan	COMPLETED
A Multi-Signal Based Monitoring System for CNS Hypersomnias	nan	UNKNOWN
Narcolepsy Protect Against Alzheimer's Disease?	nan	COMPLETED
Plasma Orexin A and mRNA Expression Levels of Pre-pro-orexin Gene in Attention-Deficit Hyperactivity Disorder	nan	UNKNOWN
Sleep Deprivation and Energy Balance	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a HCRTR2 binder may also engage these)

Protein	Name	Similarity
O62809	—	1.000	O62809 →
Q9TUP7	—	1.000	Q9TUP7 →
P58308	—	1.000	P58308 →
P56719	—	0.992	P56719 →
Q9EQD2	—	0.987	Q9EQD2 →
Q924H0	—	0.987	Q924H0 →
O97661	—	0.984	O97661 →
HCRTR1	Orexin/Hypocretin receptor type 1	0.984	landscape →
P56718	—	0.983	P56718 →
PROKR2	Prokineticin receptor 2	0.981	landscape →
Q8K458	—	0.981	Q8K458 →
Q8SPN1	—	0.980	Q8SPN1 →
Q91559	—	0.978	Q91559 →
Q9DDN6	—	0.978	Q9DDN6 →
Q9JKL1	—	0.978	Q9JKL1 →
P97295	—	0.978	P97295 →
NPY2R	Neuropeptide Y receptor type 2	0.976	landscape →
Q8SPN2	—	0.976	Q8SPN2 →
P58307	—	0.975	P58307 →
Q9Z2D5	—	0.975	Q9Z2D5 →
Q8R416	—	0.975	Q8R416 →
O02836	—	0.974	O02836 →
Q9NYM4	—	0.974	Q9NYM4 →
P79113	—	0.974	P79113 →
Q5IS62	—	0.974	Q5IS62 →
Q0GBZ5	—	0.973	Q0GBZ5 →
P30731	—	0.973	P30731 →
P25931	—	0.973	P25931 →
Q9GK74	—	0.973	Q9GK74 →
Q8R415	—	0.973	Q8R415 →